Fibroblast Activation Protein-Based Radio-Theranostics Attenuates Postinfarction Myocardial Fibrosis
ACS Applied Materials & Interfaces · 2026
DOI: 10.1021/acsami.5c25237 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2026. Verfasst von Songlu Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Beijing Chaoyang Hospital, Capital Medical University, 8th Gongtinanlu Road, Chaoyang District, Beijing 100020, China. Hauptthemen laut MEDLINE: Myocardial Infarction, Radiopharmaceuticals, Gelatinases, Membrane Proteins. Die Arbeit nennt 35 Literaturangaben. Gefördert von: National Basic Research Program of China (973 Program), National Natural Science Foundation of China (NSFC).
Abstract (Originalsprache)
Excessive fibrosis drives adverse remodeling after myocardial infarction (MI), yet targeted theranostic strategies remain limited. To enable precise diagnosis and intervention, we developed a FAP-dimer-based imaging/therapeutic platform using 68Ga-DOTA-2P(FAPI)2 for noninvasive visualization of fibroblast activation and its therapeutic analogue 177Lu-DOTA-2P(FAPI)2 for radionuclide therapy. Cardiac function and fibrosis progression were assessed by echocardiography and histopathology, biosafety was evaluated via serum biochemistry and organ staining, and single-cell RNA sequencing (scRNA-seq) was performed to elucidate the underlying mechanisms. 68Ga-DOTA-2P(FAPI)2 demonstrated a high and specific uptake in early post-MI fibrotic regions. Therapeutic administration of 177Lu-DOTA-2P(FAPI)2 at day 7 significantly reduced myocardial fibrosis and improved cardiac function in both short- and long-term (3 and 28 days) evaluations. No significant toxicity was observed within 7 days post-treatment. scRNA-seq revealed selective depletion of activated fibroblasts and suppression of pro-inflammatory signaling in the infarct border zone, confirming the antifibrotic mechanism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Beijing Chaoyang Hospital, Capital Medical University, 8th Gongtinanlu Road, Chaoyang District, Beijing 100020, China.
- Department of Nuclear Medicine, The Third Affiliated Hospital of Soochow University, No. 185, Juqian Street, Changzhou, Jiangsu Province 213003, China.
- Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan 030001, China.
- Department of Radiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
- Medical Research Center, Beijing Institute of Respiratory Medicine and Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
ORCID-Profile: Sijin Li, Min-Fu Yang
Förderung
- National Basic Research Program of China (973 Program)
- National Natural Science Foundation of China (NSFC)
Zitieren
APA
Liu, S., Li, L., Wang, Z., Xi, X. Y., Wang, Y., Li, S., Yang, Q., Zhang, X., & Yang, M. F. (2026). Fibroblast Activation Protein-Based Radio-Theranostics Attenuates Postinfarction Myocardial Fibrosis. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.5c25237
Vancouver
Liu S, Li L, Wang Z, Xi XY, Wang Y, Li S, et al. Fibroblast Activation Protein-Based Radio-Theranostics Attenuates Postinfarction Myocardial Fibrosis. ACS Applied Materials & Interfaces. 2026. doi:10.1021/acsami.5c25237
BibTeX
@article{Liu2026,
author = {Liu, Songlu and Li, Lina and Wang, Zhuxing and Xi, Xiao-Ying and Wang, Yuetao and Li, Sijin and Yang, Qi and Zhang, Xin and Yang, Min-Fu},
title = {Fibroblast Activation Protein-Based Radio-Theranostics Attenuates Postinfarction Myocardial Fibrosis},
journal = {ACS Applied Materials & Interfaces},
year = {2026},
doi = {10.1021/acsami.5c25237}
}
EUVIMED